Substance / Medication

Ipilimumab

Overview

Active Ingredient
ipilimumab
RxNorm CUI
1094833
Labeler: E.R. Squibb & Sons, L.L.C.Updated: 2025-05-28T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
The clinical benefit of adding radiotherapy to ipilimumab in patients with melanoma brain metastasis: a systematic review and meta-analysis.
Habibi Mohammad Amin, Delbari Pouria, Rashidi Farhang et al. · Clin Exp Metastasis · 2025
PMID: 39928191Meta-Analysis
The efficacy of Pembrolizumab, Ipilimumab, and Nivolumab monotherapy and combination for colorectal cancer: A systematic review and meta-analysis.
Adrianto Albertus Ari, Riwanto Ignatius, Sadhana Udadi et al. · PLoS One · 2025
PMID: 41237182Meta-AnalysisFull text (PMC)
Efficacy and safety of nivolumab plus ipilimumab versus nivolumab alone in patients with advanced melanoma: a systematic review and meta-analysis.
Cui Shuting, Sun Xiaozhe, Gao Junxi · Expert Rev Anticancer Ther · 2024
PMID: 38532600Meta-Analysis
Efficacy and safety of nivolumab plus ipilimumab in gastrointestinal cancers: a systematic review and meta-analysis.
Dai Bowen, Jiang Jiaping, Yu Xiaoyu et al. · Front Oncol · 2024
PMID: 39839773Meta-AnalysisFull text (PMC)
Efficacy and safety of the combined use of ipilimumab and nivolumab for melanoma patients with brain metastases: a systematic review and meta-analysis.
Su Mengmeng, Yang Yuyan, Wang Peng · Immunopharmacol Immunotoxicol · 2023
PMID: 37228242Meta-Analysis
A comprehensive evaluation of the safety of ipilimumab, nivolumab and their combination therapy: A systematic review and network meta-analysis.
Konwar Mahanjit, Bose Debdipta, Maurya Miteshkumar et al. · J Oncol Pharm Pract · 2023
PMID: 35147454Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Ipilimumab (substance)
SNOMED CT
697995005
UMLS CUI
C1367202
RxNorm CUI
1094833
Labeler
E.R. Squibb & Sons, L.L.C.

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.